** Shares of Atara Biotherapeutics ATRA.O rise 43% to $7.39

** Company meets with the U.S. Food and Drug Administration to discuss how to revive its application for cancer drug, tabelecleucel

** FDA agreed that a single-arm study with a historical comparison group can be enough to support a new application, Atara says

** Regulator declined to approve tabelecleucel in January, marking the second rejection after it had previously turned down the therapy over manufacturing inspection concerns

** Partner Pierre Fabre Pharmaceuticals plans to resubmit the application with updated patient data and longer follow-up from its late-stage trial

** Atara expects to share a further regulatory update in the third quarter

** Shares down 71% YTD